Judge: Cytogen does not infringe Immunomedics' patent
This article was originally published in Clinica
Executive Summary
A patent covering Immunomedics' technology for localising and treating tumours with radiolabelled antibodies is not infringed by an imaging agent belonging to rival company Cytogen, a US district judge has ruled.